The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...

Out of more than 37,000 people screened during the first 2 years after implementing universal screening in 2019, the ED ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

Theratechnologies (THTX) presented data highlighting the limitations of using body mass index alone in assessing cardiovascular risk in people ...